Literature DB >> 6813444

Carnitine deficiency and hyperammonemia associated with valproic acid therapy.

Y Ohtani, F Endo, I Matsuda.   

Abstract

Plasma carnitine and blood ammonia concentrations were measured in 25 severely handicapped patients, ages 3 to 21 years, and 27 age-matched control subjects. Fourteen of the handicapped patients were treated with anticonvulsant drugs including valproic acid; the remaining 11 patients were treated with drugs excluding valproic acid. Plasma carnitine concentrations were lower and blood ammonia values were higher in patients treated with valproic acid than in the untreated patients and control subjects. A significant inverse relationship was found between plasma carnitine concentrations and the dosage of valproic acid, and between plasma carnitine and blood ammonia values. After oral administration of D,L-carnitine (50 mg/kg/day) for four weeks, both carnitine deficiency and hyperammonemia were corrected.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6813444     DOI: 10.1016/s0022-3476(82)80320-x

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  40 in total

1.  Serum free carnitine levels during valproic acid therapy.

Authors:  S Tütüncüoglu; H Tekgül; E Levent; A Hüseyinov
Journal:  Indian J Pediatr       Date:  1997 Jul-Aug       Impact factor: 1.967

Review 2.  Valproate-induced Fanconi syndrome in a 27-year-old woman.

Authors:  Sandeep M Patel; Jonathan Graff-Radford; Mark L Wieland
Journal:  J Gen Intern Med       Date:  2011-04-23       Impact factor: 5.128

Review 3.  Delineating the role of alterations in lipid metabolism to the pathogenesis of inherited skeletal and cardiac muscle disorders: Thematic Review Series: Genetics of Human Lipid Diseases.

Authors:  Harjot K Saini-Chohan; Ryan W Mitchell; Frédéric M Vaz; Teresa Zelinski; Grant M Hatch
Journal:  J Lipid Res       Date:  2011-11-07       Impact factor: 5.922

4.  Effects of L-carnitine in patients with hepatic encephalopathy.

Authors:  Mariano Malaguarnera; Giovanni Pistone; Rampello Elvira; Carmelo Leotta; Linda Scarpello; Rampello Liborio
Journal:  World J Gastroenterol       Date:  2005-12-07       Impact factor: 5.742

5.  Case files of the Children's Hospital of Michigan Regional Poison Control Center: the use of carnitine for the management of acute valproic acid toxicity.

Authors:  Abhishek Katiyar; Cynthia Aaron
Journal:  J Med Toxicol       Date:  2007-09

6.  Valproate-induced hyperammonemic encephalopathy: a case report.

Authors:  Vikas Mangewala; Sajjad Sarwar; Ryan Rosenberger; Theodor Rais; Michele Knox
Journal:  Innov Clin Neurosci       Date:  2013-05

Review 7.  L-Carnitine.

Authors:  J H Walter
Journal:  Arch Dis Child       Date:  1996-06       Impact factor: 3.791

8.  Heterozygotes for plasmalemmal carnitine transporter defect are at increased risk for valproic acid-associated impairment of carnitine uptake in cultured human skin fibroblasts.

Authors:  I Tein; S DiMauro; Z W Xie; D C De Vivo
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

9.  Carnitine metabolism and inborn errors.

Authors:  A G Engel; C J Rebouche
Journal:  J Inherit Metab Dis       Date:  1984       Impact factor: 4.982

10.  Valproic Acid-induced hyperammonemia in the elderly: a review of the literature.

Authors:  Vikrant Mittal; Sunanda Muralee; Rajesh R Tampi
Journal:  Case Rep Med       Date:  2009-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.